ResultsIQ › Latest results › Fortis Healthcare Limited
Fortis Healthcare Limited Q2 FY27 results deck summary
NSE: FORTIS · BSE: 532843
Results deck of 5 Nov 2026, summarised by AI from the filing.
Fortis Q2 FY27 consolidated revenue rose 17.3% to ₹2,735 cr, while hospital business PAT margin fell to 12.0% from 13.4%.
Key takeaways
- Q2 revenue Consolidated revenue was ₹2,735 cr (Q2 FY26: ₹2,331 cr, up 17.3%), with PAT excluding exceptional items of ₹317 cr (up 4.0%).
- Bed aspiration Fortis aspires to reach ~12,000 beds over the next 3-5 years from ~6,300 current operational beds.
- Suguna deal In Oct'26 Fortis acquired the 110-bedded Suguna Hospital in Bengaluru in an all-cash deal for ~₹277 cr.
- Margin risk Hospital business PAT margin fell to 12.0% from 13.4% in Q2 FY26 even as revenue grew 18.6%.
Fortis Healthcare Limited Q2 FY27 results
As filed: Revenue ₹2,735 cr (+17% year on year), EBITDA ₹623 cr (+12% year on year), PAT ₹320 cr (−3% year on year), EBITDA margin 22.8% (−107 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹2,545 cr (+17% year on year), EBITDA ₹537 cr (+9% year on year), PAT ₹273 cr (+2% year on year), EBITDA margin 21.1% (−155 bps). Score 35 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 155 bps year on year. Share price after the results: −1.6% in 29 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹2,365 cr (+18% year on year), EBITDA ₹532 cr (+22% year on year), PAT ₹271 cr (+44% year on year), EBITDA margin 22.5% (+79 bps). Score 65 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was in line with it. EBITDA margin rose 79 bps year on year. Revenue rose ₹358 cr on a year ago, more than the ₹221 cr it added the year before. Share price after the results: +0.3% in 28 days (Nifty 500: +2.2%).
- Q3 FY26: Revenue ₹2,265 cr (+17% year on year), EBITDA ₹506 cr (+35% year on year), PAT ₹197 cr (+22% year on year), EBITDA margin 22.3% (+293 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 293 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Profit fell 23% from last quarter. Share price after the results: −8.4% in 28 days (Nifty 500: −8.2%).
- Q2 FY26: Revenue ₹2,331 cr (+17% year on year), EBITDA ₹556 cr (+28% year on year), PAT ₹329 cr (+70% year on year), EBITDA margin 23.9% (+197 bps). Score 66 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 197 bps year on year. Revenue rose ₹343 cr on a year ago, more than the ₹218 cr it added the year before. Share price after the results: −13.3% in 30 days (Nifty 500: −0.6%).
- Q1 FY26: Revenue ₹2,167 cr (+17% year on year), EBITDA ₹491 cr (+44% year on year), PAT ₹267 cr (+53% year on year), EBITDA margin 22.7% (+426 bps). Score 80 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin rose 426 bps year on year. Revenue rose ₹308 cr on a year ago, more than the ₹202 cr it added the year before. Share price after the results: +10.5% in 30 days (Nifty 500: +0.7%).
- Q4 FY25: Revenue ₹2,007 cr (+12% year on year), EBITDA ₹436 cr (+14% year on year), PAT ₹188 cr (+8% year on year), EBITDA margin 21.7% (+39 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin rose 39 bps year on year. Share price after the results: +10.2% in 30 days (Nifty 500: +0.8%).
- Q3 FY25: Revenue ₹1,928 cr (+15% year on year), EBITDA ₹374 cr (+32% year on year), PAT ₹254 cr (+90% year on year), EBITDA margin 19.4% (+249 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 249 bps year on year. Tax rate 9%. Revenue fell 3% from last quarter.
Past price moves after results do not indicate future moves. Not a recommendation.
Fortis Healthcare Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (6 Nov 2026), Results deck (5 Nov 2026)
- Q1 FY27: Earnings call (7 Aug 2026), Results deck (6 Aug 2026)
- Q4 FY26: Earnings call (25 May 2026), Results deck (22 May 2026)
- Q3 FY26: Earnings call (16 Feb 2026), Results deck (13 Feb 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results deck (11 Nov 2025), Results deck (8 Jan 2026)
- Q1 FY26: Earnings call (7 Aug 2025), Results deck (6 Aug 2025)
- Q4 FY25: Earnings call (21 May 2025), Results deck (20 May 2025)
- Other events: Special call (4 Sep 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.